我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
2
66.7%
招募中
1
33.3%
暂无批准数据
- Phraxis Inc. has received FDA approval for EndoForce™ Connector, an innovative endovascular implant designed to simplify arteriovenous graft creation for hemodialysis patients. - The device demonstrated strong clinical performance in a pivotal multicenter study, achieving a 92% cumulative patency rate at six months and meeting all primary and secondary endpoints. - EndoForce™ eliminates the need for surgical venous dissection and promotes precise vessel-to-graft alignment, potentially reducing complications like intimal hyperplasia at the anastomosis site.
